GlassScriptPhysician profile
Masoud Soroudi
NPI 1851770929
$3,876.40
in general payments reported to CMS, 2019-2025
15 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $433 · 2023: $634 · 2024: $1,241 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.44 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $498.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $480.27 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.35 | 2023-2025 | Caplyta |
| Lundbeck LLC | $420.38 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $360.49 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $298.58 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $174.49 | 2023-2024 | Azstarys |
| Bausch Health US, LLC | $163.93 | 2024-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $80.08 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $58.13 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $26.87 | 2024 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $20.51 | 2025 | Trintellix |
| Almatica Pharma LLC | $18.64 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $14.00 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masoud Soroudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.